Peplin clinical trials
Acquired by LEO Pharma, Nov 11, 2009 · source ↗
The registry lists 29 studies whose lead sponsor is Peplin. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 5, 2016.
Before and after it joined LEO Pharma
- First submitted before Peplin became part of LEO Pharma
- 25
- First submitted after Peplin became part of LEO Pharma
- 4
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Status
- Completed
- 28
- Withdrawn
- 1
Registry sponsor names on this page
- Peplin29 studies
Something wrong with this grouping? Tell us on the LEO Pharma page.
Studies
Recruiting first, then most recently updated. Showing 29 of 29. All LEO Pharma studies →
- Study to Determine the Sensitizing Potential of PEP005 Topical Gel in Healthy Volunteers Using a Repeat Insult Patch Test DesignCompletedNCT00357916Phase 1
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or ExtremitiesCompletedNCT01325688Phase 2
Sponsor listed in the registry: Peplin · First submitted after Peplin became part of LEO Pharma
- To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCCCompletedNCT00432185Phase 2
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic KeratosesCompletedNCT00375739Phase 2
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s)WithdrawnNCT00546611Phase 1
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- PEP005 Gel - Evaluation of Local Tolerability After Exposure to Ingenol Mebutate Gel Followed by Hand Washing in Healthy SubjectsCompletedNCT01302925Phase 1
Sponsor listed in the registry: Peplin · First submitted after Peplin became part of LEO Pharma
- A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical GelCompletedNCT00427050Phase 2
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2CompletedNCT00659893Phase 1
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy VolunteersCompletedNCT00850681Phase 1
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy VolunteersCompletedNCT00850811Phase 1
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- A Multi-center Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on Non-head Locations (Trunk and Extremities)CompletedNCT00917306Phase 3
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- A Multicenter Study to Evaluate the Safety and Efficacy of PEP005 Topical Gel When Used to Treat Actinic Keratoses on the Head (Face or Scalp)CompletedNCT00700063Phase 2
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)CompletedNCT00916006Phase 3
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- A Study to Examine the Safety and Toleration of PEP005 Topical Gel in Patients With Actinic Keratoses on the Top of the HandCompletedNCT00544297Phase 2
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 StudyCompletedNCT00989313
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 StudiesCompletedNCT00953732
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- A Long Term Follow up Study of Patients Who Have Completed the PEP005-020 StudyCompletedNCT00952783
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Actinic KeratosesCompletedNCT00107965Phase 2
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical GelCompletedNCT00239135Phase 2
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head LocationsCompletedNCT00742391Phase 3
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head LocationsCompletedNCT00942604Phase 3
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic KeratosisCompletedNCT00852137Phase 2
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)CompletedNCT00915551Phase 3
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005CompletedNCT00544258Phase 1
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Cutaneous Squamous Cell Carcinoma In SituCompletedNCT00329121Phase 2
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell CarcinomaCompletedNCT00108121Phase 2
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma
- Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic KeratosisCompletedNCT01214564Phase 2
Sponsor listed in the registry: Peplin · First submitted after Peplin became part of LEO Pharma
- Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged SkinCompletedNCT01214577Phase 2
Sponsor listed in the registry: Peplin · First submitted after Peplin became part of LEO Pharma
- Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Superficial Basal Cell CarcinomaCompletedNCT00108134Phase 2
Sponsor listed in the registry: Peplin · First submitted before Peplin became part of LEO Pharma